Skip to main content
GWGovwatch
CongressBillsCommitteesPresidentMoneyPulseMisconductElectionsMap
Donate

Weekly accountability digest

One email a week with new votes, moving bills, and misconduct updates. No spam.

GW

Govwatch. Public data about Congress, in one place, in plain English.

Built with public data. Not affiliated with the U.S. government.

Explore

  • Officials
  • Legislation
  • Committees
  • Congress Pulse
  • Trending Topics
  • Bipartisan Leaderboard
  • Weekly Digest
  • Misconduct
  • Predictions

Learn

  • How Congress Works
  • How a Bill Becomes Law
  • Campaign Finance 101
  • Glossary

Tools

  • My Representatives
  • Compare Members
  • Bill Watchlist
  • Search
  • District Map
  • Follow the Money
  • Watch Live

Site

  • About
  • Contact
  • Corrections
  • Privacy Policy
  • Terms of Service

Data Sources

Congress.gov API v3
Bills, members, votesGovInfo API
Floor speeches, reports, bill textFederal Election Commission (FEC)
Campaign financeVoteView (UCLA)
Ideology scores (DW-NOMINATE)GovTrack.us
Misconduct data (CC0)U.S. Census Bureau
District demographics
Support This Project

This site is free. Donations help cover hosting, API fees, and keeping the data fresh.

All data is sourced from official government APIs and public records. This site is for informational purposes only.

© 2026 Govwatch

HR5343Referred to Committee

Ensuring Patient Access to Critical Breakthrough Products Act

Share:
Introduced
In Committee
3
Passed One Chamber
4
Passed Both
5
Signed into Law
119th
Congress
2025-09-15
Introduced
51
Cosponsors
HR
ⓘ
Type

Sponsor

Blake D. Moore
Blake D. Moore
Republican · UT · Representative
Votes with party: 98.2% (552 recorded votes)

Full profile: /officials/M001213

Source: Congress.gov · FEC

Cosponsors (51)

Members who have signed on to support this bill since introduction. Source: Congress.gov.

  • Gus M. Bilirakis (R-FL-12)Original· 2025-09-15
  • Lori Trahan (D-MA-3)Original· 2025-09-15
  • Rudy Yakym III (R-IN-2)Original· 2025-09-15
  • Suzan K. DelBene (D-WA-1)Original· 2025-09-15
  • Terri A. Sewell (D-AL-7)Original· 2025-09-15
  • Claudia Tenney (R-NY-24)· 2025-09-16
  • Michelle Fischbach (R-MN-7)· 2025-09-16
  • Bradley Scott Schneider (D-IL-10)· 2025-09-17
  • J. Luis Correa (D-CA-46)· 2025-09-19
  • Earl L. "Buddy" Carter (R-GA-1)· 2025-10-31
  • Jake Auchincloss (D-MA-4)· 2025-10-31
  • Carol D. Miller (R-WV-1)· 2025-11-07
  • Ted Lieu (D-CA-36)· 2025-11-07
  • Ami Bera (D-CA-6)· 2025-11-18
  • Burgess Owens (R-UT-4)· 2025-11-18
  • Darren Soto (D-FL-9)· 2025-12-02
  • Randy K. Weber, Sr. (R-TX-14)· 2025-12-02
  • Chris Pappas (D-NH-1)· 2025-12-09
  • Jennifer A. Kiggans (R-VA-2)· 2025-12-09
  • Aaron Bean (R-FL-4)· 2025-12-17
  • Jimmy Panetta (D-CA-19)· 2026-01-06
  • Cliff Bentz (R-OR-2)· 2026-01-14
  • Deborah K. Ross (D-NC-2)· 2026-01-14
  • Brittany Pettersen (D-CO-7)· 2026-02-03
  • Josh Gottheimer (D-NJ-5)· 2026-02-03
  • Marilyn Strickland (D-WA-10)· 2026-02-03
  • Michael Lawler (R-NY-17)· 2026-02-03
  • Mike Carey (R-OH-15)· 2026-02-03
  • Nicole Malliotakis (R-NY-11)· 2026-02-03
  • Brian K. Fitzpatrick (R-PA-1)· 2026-02-10
  • Zoe Lofgren (D-CA-18)· 2026-02-10
  • Celeste Maloy (R-UT-2)· 2026-02-11
  • Chrissy Houlahan (D-PA-6)· 2026-02-11
  • John Joyce (R-PA-13)· 2026-02-11
  • Steve Cohen (D-TN-9)· 2026-02-11
  • Angie Craig (D-MN-2)· 2026-03-16
  • Daniel Meuser (R-PA-9)· 2026-03-16
  • David G. Valadao (R-CA-22)· 2026-04-02
  • George Whitesides (D-CA-27)· 2026-04-02
  • Brendan F. Boyle (D-PA-2)· 2026-04-09
  • Jason Crow (D-CO-6)· 2026-04-09
  • Jay Obernolte (R-CA-23)· 2026-04-09
  • Juan Ciscomani (R-AZ-6)· 2026-04-09
  • Maggie Goodlander (D-NH-2)· 2026-04-16
  • Mike Kennedy (R-UT-3)· 2026-04-16
  • Gregory F. Murphy (R-NC-3)· 2026-05-14
  • Kevin Mullin (D-CA-15)· 2026-05-14

Latest Action

The most recent step in the bill's legislative path. Committee Activity below shows referrals and reports; the full action-by-action history including floor proceedings lives at Congress.gov →

Ordered to be Reported in the Nature of a Substitute (Amended) by the Yeas and Nays: 37 - 3.

2025-09-17

Source: Congress.gov

Committee Activity

Currently in

  • House Committee on Ways and MeansMarkup By · 2025-09-17
  • House Committee on Energy and CommerceReferred To · 2025-09-15

Previously

  • Ways and Means CommitteeMarkup By · 2025-09-17
  • Ways and Means CommitteeReferred To · 2025-09-15
  • Energy and Commerce CommitteeReferred To · 2025-09-15
  • House Committee on Ways and MeansReferred To · 2025-09-15

Plain-English Summary

This bill would make it easier for patients to access new breakthrough medications and medical treatments by streamlining the approval process and reducing regulatory barriers at the FDA. The legislation aims to help patients with serious or life-threatening conditions get faster access to promising new drugs and devices that show potential to treat their diseases. The bill affects pharmaceutical companies, patients, healthcare providers, and the FDA's approval procedures.

AI-assisted summary generated from the official bill metadata (title, subjects, actions) sourced from Congress.gov. Cached and reviewed. Always verify against the official text linked below.

Subjects

Health
Full bill text is not yet cached locally.
Open text viewRead on Congress.gov

Related legislation

Bills by the same sponsor or covering overlapping subjects.

  • HR6949Upward Mobility Act of 2026
    Referred to Committee · 2026-05-20
  • HR8780Critical Mineral and Extraction Tax Parity Act
    Referred to Committee · 2026-05-13
  • HR8757Promoting Childhood Independence and Resilience Act of 2026
    Referred to Committee · 2026-05-12
  • HR8623GUARD Act
    Referred to Committee · 2026-04-30